We recently published a list of Jim Cramer Commented On These 6 Stocks Recently. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY)) stands against other stocks that Jim Cramer commented discussed recently.

Whatever you think of Donald Trump’s tariff policies, one fact stands out: companies are looking to invest more in the United States. They want to avoid the negative impacts of tariffs on their business.

Eli Lilly and Company (NYSE: LLY) will participate in Leerink Partners Global Healthcare Conference on March 10, 2025. Lucas Montarce, Lilly executive vice president and chief financial officer ...

Pharmaceutical giant expects the move will create 3,000 high-skilled jobs and provide work for approximately 10,000 construction workers.

Eli Lilly partnered up with telehealth providers LifeMD and Teladoc Health to offer its lower cost, single-vial Zepbound (tirzepatide) to patients in the virtual c | The move could be a boon for telehealth weight loss programs,

Eli Lilly and Co. is in negotiations with several states and plans to announce the locations of four new manufacturing plants later this year.

Eli Lilly announced plans for four new pharmaceutical manufacturing sites to produce domestic medicine production in the United States and make the nation the world's leader in pharmaceutical production.

Eli Lilly Chief Executive David Ricks annual compensation rose to $29.2 million in 2024, a 10% increase from the $26.2 million he received a year earlier.

A federal court in Texas has rejected a request by producers of compounded drugs to extend their ability to manufacture knockoff versions of Eli Lilly's tirzepatide while a lawsuit plays out. | A Texas court has rejected a request by compounders to extend their ability to manufacture knockoff versions of Eli Lilly's tirzepatide while a lawsuit plays out.

Eli Lilly is partnering with Imagine Entertainment and MACRO to drive industry-wide change and guide in authentically representing disease.

The partnership comes as telehealth companies grapple with restrictions on the sale of some compounded GLP-1s.

Eli Lilly has lowered the price of its weight-loss drug Zepbound for patients paying out of pocket and introduced two new available vial doses.